Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benglouting granules
- Development stage
- Phase 2
- Lead developer
- Shuyang Chenggui Hospital
- Administration
- Oral
01
Overview
Benglouting granules is a Traditional Chinese Medicine (TCM) formulation developed by Shuyang Chenggui Hospital for the treatment of abnormal uterine bleeding (AUB), specifically menorrhagia. In TCM theory, it is indicated for patients exhibiting the 'blood stasis' pattern. The product is administered orally as granules. It has been evaluated in a Phase 2 randomized, double-blind, placebo-controlled clinical trial in China to assess its efficacy and safety in reducing excessive menstrual blood loss and managing symptoms of flooding and leaking.
- Brand names
- Benglouting granules
- Other names
- Benglouting keliBeng Lou Ting
Beyond the preview
Go deeper on Benglouting granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Benglouting granules.